Asset profile
GK1-399 (formerly TTP399)
Small molecule
Evidence outlook · no controlled comparison
NCT01474083 · Type 2 Diabetes Mellitus
The lead study's design has limits that temper confidence (see the rationale below), and it produced no formal comparison against a control. This tier describes the design, not an outcome.
NCT01474083: The study was randomized, quadruple-blind, and placebo-controlled, with 248 participants across three GK1-399 dose groups and a placebo group. Its primary endpoint was a pharmacokinetic measure, a surrogate rather than a clinical outcome, and no primary endpoint results are posted.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
65 competitors in this universe: 5 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 63 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| GK1-399 (formerly TTP399): this drug | Phase 1/2 | Small molecule | Glucokinase | ||
| Dorzagliatin (Huatangning) | Phase 3 | Small molecule | Glucokinase | ||
| PB-201 | Phase 3 | Small molecule | Glucokinase | ||
| SY-004 | Phase 2 | Small molecule | Glucokinase | ||
| Globalagliatin Hydrochloride | Phase 1 | Small molecule | Glucokinase | ||
| HMS1005 | Phase 1 | Small molecule | Glucokinase | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ertugliflozin (Steglatro) | Approved | Small molecule | SGLT2 | ||
| Glipizide (Glucotrol) | Approved | Small molecule | Sulfonylurea receptor (SUR1) | ||
| Glyburide (Diabeta / Micronase) | Approved | Small molecule | Sulfonylurea receptor (SUR1) |
…and 50 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.